Q4 2026 Natco Pharma Ltd Earnings Call Transcript
Key Points
- Natco Pharma Ltd (BOM:524816) recorded consolidated total revenue of INR4,375.9 crores for the year ended March 31, 2026.
- The company has a diversified revenue stream with significant contributions from markets like Brazil, Canada, and South Africa.
- Natco Pharma Ltd (BOM:524816) has a strong oncology pipeline and is expecting significant launches in Brazil and Canada in the coming years.
- The company has a net cash position of INR2,400 crores, providing a strong financial base for potential acquisitions.
- Natco Pharma Ltd (BOM:524816) is focusing on geographical diversification to reduce earnings volatility and build a stable global presence.
- The company's net profit for the year declined to INR1,418.5 crores from INR1,883.4 crores last year.
- Revenue for the fourth quarter decreased to INR816.9 crores from INR1,287.3 crores in the same period last year.
- There was a significant impact on sales due to the competitive nature of the Revlimid market.
- Higher R&D expenses and engineering write-downs contributed to increased other expenses this quarter.
- The company anticipates a challenging FY 2027 with expected revenue and profit declines compared to previous years.
Ladies and gentlemen, good day, and welcome to the NATCO Pharma's Q4 FY 2026 earnings conference call, hosted by 360 ONE Capital Markets Private Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Hrishikesh Patole from 360 ONE Capital Markets Private Limited. Thank you, and over to you, sir. Ladies and gentlemen, the line for Mr. Hrishikesh has been disconnected. Please stay connected while we join them back. Ladies and gentlemen, the line for Mr. Hrishikesh Patole has been connected. Thank you, and over to you, sir.
Thank you. Apologies for the delay. Good afternoon, everyone. On behalf of 360 ONE, I welcome you all to the Q4 FY 2026 earnings conference call of NATCO Pharma. Hope everyone is in good health and doing well. On behalf of NATCO today, we have with us Mr. Rajeev Nannapaneni, Vice Chairman and CEO; Mr. Amit Parekh, CFO; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences; and Mr. Rajeev
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
